Table 2.
Cases of combined lobular and ductal carcinoma
| Lobular component | Ductal component | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case number | Age (year) | Clinical stage | Type | Grade | E/P/H | Size (cm) | Type | Grade | E/P/H | Size (cm) | Posional relation |
| 1 | 75 | 0 | LCIS | 1 | +/+/− | – | DCIS | 1 | +/+/− | – | C |
| 2 | 44 | 0 | LCIS | 1 | +/+/− | – | DCIS | 1 | +/+/− | – | C |
| 3 | 43 | 0 | LCIS | 1 | +/−/− | – | DCIS | 2 | +/+/− | – | C |
| 4 | 50 | 0 | LCIS | 1 | +/+/− | – | DCIS | 2 | +/+/− | – | C |
| 5 | 43 | I | LCIS | 1 | +/+/− | – | IDC | 1 | +/+/− | 0.4 | C |
| 6 | 47 | I | LCIS | 1 | +/+/− | – | IDC | 1 | +/+/− | 1.2 | C |
| 7 | 50 | I | LCIS | 1 | +/+/− | – | IDC | 1 | +/+/− | 1.3 | C |
| 8 | 35 | I | LCIS | 1 | +/+/− | – | IDC* | 2 | +/+/− | 1.4 | C |
| 9 | 42 | IIA | LCIS | 1 | +/+/− | – | IDC | 2 | +/+/− | 1 | C |
| 10 | 43 | I | ILC | 2 | +/+/− | 1.5 | DCIS | 1 | +/+/− | – | C |
| 11 | 53 | I | ILC | 1 | +/+/− | 1.5 | DCIS | 2 | +/+/− | – | S |
| 12 | 58 | IIA | ILC | 2 | +/−/− | 2.2 | DCIS | 2 | +/−/− | – | C |
| 13 | 75 | IIB | ILC | 2 | +/−/− | 3.5 | DCIS | 2 | +/−/− | – | C |
| 14 | 73 | IIA | ILC | 1 | +/+/− | 4 | DCIS | 2 | +/+/− | – | C |
| 15 | 51 | IIA | ILC | 1 | +/+/− | 4 | IDC | 2 | +/+/− | 3.5 | U |
| Average | 52.1 | – | – | – | – | 2.8 | – | – | – | 1.5 | – |
C, contiguous; DCIS, ductal carcinoma in situ; E, estrogen receptor; H, human epidermal growth factor receptor 2(HER2); IDC*, IDC + DCIS; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; P, progesterone receptor; S, separate; U, unknown.